LifeVantage (LFVN) Water Tower Fireside Chat Series summary

Product innovation and launch

• Introduced MindBody GLP-1 System, a nutrigenomics-based supplement targeting weight management and cellular health, following over a year of development and clinical testing.

• Human clinical study showed a 140% increase in GLP-1 production, up to 27% reduction in visceral fat, and up to 5% overall fat loss, with no muscle mass lost.

• Product launch in Kansas City generated significant excitement, selling out five times the initial inventory of a previous major launch in just 13 days.

• Patent filed for the new product, with expectations for approval in about two years.

• Backorders are being addressed, with inventory expected to be replenished and shipping to resume by late December.

Business performance and outlook

• October saw record bookings, 20% higher than any previous month, with continued strong demand despite inventory shortages.

• Consultant recruitment in October was five times the trailing 12-month weekly average, remaining elevated.

• No immediate forecast revision post-launch due to supply chain uncertainties, but more clarity expected with Q2 results in early 2024.

• MindBody launch is expected to drive top-line growth and attract new demographics, expanding the customer base.

International expansion and strategy

• U.S. launch to be followed by international rollouts, with most countries, including Japan, launching in March-April; some markets will follow later due to regulatory timelines.

• International strategy mirrors U.S. approach: education, consultant engagement, and pre-launch product experiences.

• MindBody is positioned as a catalyst to reengage international markets and cross-sell other products.